Our research focuses on the identification of novel cancer-susceptibility genes using genomic technologies. We are specifically interested in helping to determine the genetic basis of “sporadic” cancers in young adults and children. By comparing germline genomes of cancer case-parent trios, the identification of de novo germline mutations is possible; such mutations appear to account for cancer susceptibility in some cancer-affected young adults and children. We are also using next-generation sequencing technologies for detection of novel cancer susceptibility loci in individuals with a familial predisposition to cancer. Ultimately, the goal of our translational research is to better understand the genetic basis of cancers, which could lead to improvements in cancer risk stratification and prevention. Our current work is supported by the Damon Runyon Cancer Research Foundation, an R21 grant from the National Cancer Institute, the Starr Cancer Consortium, and Cycle for Survival.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Zsofia K. Stadler discloses the following relationships and financial interests:
Professional Services and Activities (Uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.